<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37500292</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>31</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2053-8790</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Lupus science &amp; medicine</Title><ISOAbbreviation>Lupus Sci Med</ISOAbbreviation></Journal><ArticleTitle>Clarifying misbeliefs about hydroxychloroquine (HCQ): developing the HCQ benefits versus harm decision aid (HCQ-SAFE) per low health literacy standards.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e000935</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/lupus-2023-000935</ELocationID><Abstract><AbstractText Label="BACKGROUND">Up to 83% of patients with SLE stop taking hydroxychloroquine (HCQ) within the first year due to knowledge gaps regarding the survival benefits of HCQ versus inflated fears of rare toxicity. Thus, there is a need for a shared decision-making tool that highlights HCQ's significant benefits versus rare harms to improve patients' understanding and align treatments with their values. The objective of this study was to describe development and piloting of a decision aid (HCQ-SAFE) to facilitate HCQ adherence, and safe, effective use by engaging patients in therapeutic decision-making.</AbstractText><AbstractText Label="METHODS">HCQ-SAFE was developed via a collaborative process involving patients, clinicians, implementation scientists and health literacy experts. The initial prototype was informed by Agency for Healthcare Research and Quality (AHRQ) low literacy principles and key themes about HCQ use from six prior patient and clinician focus groups, with iterative expert and stakeholder feedback to deliver a final prototype. We implemented HCQ-SAFE in four clinics to examine usability and feasibility on Likert scales (0-7) and net promoter score (0%-100%).</AbstractText><AbstractText Label="RESULTS">The final HCQ-SAFE shared decision-making laminated tool organises data using pictograms showing how HCQ use reduces risk of organ damage, early death and blood clots versus low risk of eye toxicity.HCQ-SAFE was reviewed in all eligible patient visits (n=40) across four clinics on an average of ~8&#x2009;min, including 25% non-English-speaking patients. All patients scored 100% on the knowledge post-test; no decisional conflicts were noted after using HCQ-SAFE. HCQ-SAFE garnered high clinician and patient satisfaction with 100% likelihood to recommend to peers.</AbstractText><AbstractText Label="CONCLUSIONS">HCQ-SAFE is a stakeholder-informed feasible shared decision-making tool that enhances communication and can potentially improve knowledge, clarify misbeliefs and engage patients in treatment decisions, including those with limited English proficiency.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Garg</LastName><ForeName>Shivani</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-7272-2692</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Division of Rheumatology, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, USA sgarg@medicine.wisc.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferguson</LastName><ForeName>Sancia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Rheumatology, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chewning</LastName><ForeName>Betty</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, School of Pharmacy, Madison, Wisconsin, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gomez</LastName><ForeName>Shelby</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, School of Pharmacy, Madison, Wisconsin, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keevil</LastName><ForeName>Jon</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Madison, Wisconsin, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bartels</LastName><ForeName>Christie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Rheumatology, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UL1 TR002373</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus Sci Med</MedlineTA><NlmUniqueID>101633705</NlmUniqueID><ISSNLinking>2053-8790</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057220" MajorTopicYN="Y">Health Literacy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003661" MajorTopicYN="N">Decision Support Techniques</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">lupus erythematosus, systemic</Keyword><Keyword MajorTopicYN="N">outcome assessment, health care</Keyword><Keyword MajorTopicYN="N">patient care team</Keyword><Keyword MajorTopicYN="N">qualitative research</Keyword><Keyword MajorTopicYN="N">therapeutics</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>28</Day><Hour>1</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>27</Day><Hour>21</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37500292</ArticleId><ArticleId IdType="pmc">PMC10387621</ArticleId><ArticleId IdType="doi">10.1136/lupus-2023-000935</ArticleId><ArticleId IdType="pii">10/2/e000935</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, et al. . Clinical efficacy and side effects of Antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010;69:20&#x2013;8. 10.1136/ard.2008.101766</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2008.101766</ArticleId><ArticleId IdType="pubmed">19103632</ArticleId></ArticleIdList></Reference><Reference><Citation>Floris A, Piga M, Mangoni AA, et al. . Protective effects of hydroxychloroquine against accelerated Atherosclerosis in systemic lupus erythematosus. Mediators Inflamm 2018;2018. 10.1155/2018/3424136</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/3424136</ArticleId><ArticleId IdType="pmc">PMC5835241</ArticleId><ArticleId IdType="pubmed">29670462</ArticleId></ArticleIdList></Reference><Reference><Citation>Nuri E, Taraborelli M, Andreoli L, et al. . Long-term use of hydroxychloroquine reduces Antiphospholipid antibodies levels in patients with primary Antiphospholipid syndrome. Immunol Res 2017;65:17&#x2013;24. 10.1007/s12026-016-8812-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12026-016-8812-z</ArticleId><ArticleId IdType="pubmed">27406736</ArticleId></ArticleIdList></Reference><Reference><Citation>Fessler BJ, Alarc&#xf3;n GS, McGwin G, et al. . Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 2005;52:1473&#x2013;80. 10.1002/art.21039</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.21039</ArticleId><ArticleId IdType="pubmed">15880829</ArticleId></ArticleIdList></Reference><Reference><Citation>Alarc&#xf3;n GS, McGwin G, Bertoli AM, et al. . Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a Multiethnic US cohort (LUMINA L). Ann Rheum Dis 2007;66:1168&#x2013;72. 10.1136/ard.2006.068676</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2006.068676</ArticleId><ArticleId IdType="pmc">PMC1955128</ArticleId><ArticleId IdType="pubmed">17389655</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehat P, Atiquzzaman M, Esdaile JM, et al. . Medication Nonadherence in systemic lupus erythematosus: a systematic review. Arthritis Care Res (Hoboken) 2017;69:1706&#x2013;13. 10.1002/acr.23191</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.23191</ArticleId><ArticleId IdType="pubmed">28086003</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman CH, Collins J, Zhang Z, et al. . Dynamic patterns and predictors of hydroxychloroquine Nonadherence among Medicaid beneficiaries with systemic lupus erythematosus. Semin Arthritis Rheum 2018;48:205&#x2013;13. 10.1016/j.semarthrit.2018.01.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2018.01.002</ArticleId><ArticleId IdType="pmc">PMC6035896</ArticleId><ArticleId IdType="pubmed">29458974</ArticleId></ArticleIdList></Reference><Reference><Citation>American College of Rheumatology . Association between hydroxychloroquine Nonadherence and adverse outcomes among patients with systemic lupus erythematosus [abstract]. Arthritis Rheumatol 2017.</Citation></Reference><Reference><Citation>Canadian Hydroxychloroquine Study Group . A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991;324:150&#x2013;4. 10.1056/NEJM199101173240303</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199101173240303</ArticleId><ArticleId IdType="pubmed">1984192</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai T, Zhao J, Yang Y, et al. . Hydroxychloroquine use reduces mortality risk in systemic lupus erythematosus: a systematic review and meta-analysis of cohort studies. Lupus 2022;31:1714&#x2013;25. 10.1177/09612033221129774</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033221129774</ArticleId><ArticleId IdType="pubmed">36325952</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldman CH, Yazdany J, Guan H, et al. . Medication Nonadherence is associated with increased subsequent acute care utilization among Medicaid beneficiaries with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2015;67:1712&#x2013;21. 10.1002/acr.22636</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.22636</ArticleId><ArticleId IdType="pmc">PMC4684806</ArticleId><ArticleId IdType="pubmed">26097166</ArticleId></ArticleIdList></Reference><Reference><Citation>Tse K, Daly RP. 232&#x2005;predictors of hydroxychloroquine treatment adherence among people with lupus. 13th International Congress on Systemic LUPUS Erythematosus (LUPUS 2019), San Francisco, California, USA, April 5&#x2013;8, 2019, Abstract Presentations; 2019. 10.1136/lupus-2019-lsm.232</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2019-lsm.232</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia Popa-Lisseanu MG, Greisinger A, Richardson M, et al. . Determinants of treatment adherence in ethnically diverse, economically disadvantaged patients with rheumatic disease. J Rheumatol 2005;32:913&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">15868630</ArticleId></ArticleIdList></Reference><Reference><Citation>Chambers SA, Raine R, Rahman A, et al. . Why do patients with systemic lupus erythematosus take or fail to take their prescribed medications? A qualitative study in a UK cohort. Rheumatology (Oxford) 2009;48:266&#x2013;71. 10.1093/rheumatology/ken479</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/ken479</ArticleId><ArticleId IdType="pubmed">19151034</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Gonzalez A, Richardson M, Garcia Popa-Lisseanu M, et al. . Treatment adherence in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Rheumatol 2008;27:883&#x2013;9. 10.1007/s10067-007-0816-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-007-0816-6</ArticleId><ArticleId IdType="pubmed">18185905</ArticleId></ArticleIdList></Reference><Reference><Citation>Garg S, Chewning B, Gazeley D, et al. . Patient and Healthcare team recommended medication adherence strategies for hydroxychloroquine: results of a qualitative study informing intervention development. Lupus Sci Med 2022;9. 10.1136/lupus-2022-000720</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2022-000720</ArticleId><ArticleId IdType="pmc">PMC9345084</ArticleId><ArticleId IdType="pubmed">35914839</ArticleId></ArticleIdList></Reference><Reference><Citation>Costedoat-Chalumeau N, Amoura Z, Hulot J-S, et al. . Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus. Ann Rheum Dis 2007;66:821&#x2013;4. 10.1136/ard.2006.067835</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2006.067835</ArticleId><ArticleId IdType="pmc">PMC1954674</ArticleId><ArticleId IdType="pubmed">17324970</ArticleId></ArticleIdList></Reference><Reference><Citation>Drenkard C, Bao G, Lewis TT, et al. . Physician-patient interactions in African American patients with systemic lupus erythematosus: demographic characteristics and relationship with disease activity and depression. Semin Arthritis Rheum 2019;48:669&#x2013;77. 10.1016/j.semarthrit.2018.05.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2018.05.012</ArticleId><ArticleId IdType="pmc">PMC6509352</ArticleId><ArticleId IdType="pubmed">30075991</ArticleId></ArticleIdList></Reference><Reference><Citation>Chambers S, Raine R, Rahman A, et al. . Factors influencing adherence to medications in a group of patients with systemic lupus erythematosus in Jamaica. Lupus 2008;17:761&#x2013;9. 10.1177/0961203308089404</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203308089404</ArticleId><ArticleId IdType="pubmed">18625657</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar K, Gordon C, Barry R, et al. . It&#x2019;s like taking poison to kill poison but I have to get better': a qualitative study of beliefs about medicines in rheumatoid arthritis and systemic lupus erythematosus patients of South Asian origin. Lupus 2011;20:837&#x2013;44. 10.1177/0961203311398512</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203311398512</ArticleId><ArticleId IdType="pubmed">21511761</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenfield S, Kaplan S, Ware JE. Expanding patient involvement in care. Ann Intern Med 1985;102:520. 10.7326/0003-4819-102-4-520</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-102-4-520</ArticleId><ArticleId IdType="pubmed">3977198</ArticleId></ArticleIdList></Reference><Reference><Citation>Oshima Lee E, Emanuel EJ. Shared decision making to improve care and reduce costs. N Engl J Med 2013;368:6&#x2013;8. 10.1056/NEJMp1209500</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMp1209500</ArticleId><ArticleId IdType="pubmed">23281971</ArticleId></ArticleIdList></Reference><Reference><Citation>DuBard CA, Gizlice Z. Language spoken and differences in health status, access to care, and receipt of preventive services among US Hispanics. Am J Public Health 2008;98:2021&#x2013;8. 10.2105/AJPH.2007.119008</Citation><ArticleIdList><ArticleId IdType="doi">10.2105/AJPH.2007.119008</ArticleId><ArticleId IdType="pmc">PMC2636430</ArticleId><ArticleId IdType="pubmed">18799780</ArticleId></ArticleIdList></Reference><Reference><Citation>Barton JL, Koenig CJ, Evans-Young G, et al. . The design of a low literacy decision aid about rheumatoid arthritis medications developed in three languages for use during the clinical encounter. BMC Med Inform Decis Mak 2014;14:104. 10.1186/s12911-014-0104-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12911-014-0104-8</ArticleId><ArticleId IdType="pmc">PMC4363399</ArticleId><ArticleId IdType="pubmed">25649726</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh JA, Fraenkel L, Green C, et al. . Individualized decision aid for diverse women with lupus nephritis (IDEA-WON): A randomized controlled trial. PLoS Med 2019;16. 10.1371/journal.pmed.1002800</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1002800</ArticleId><ArticleId IdType="pmc">PMC6505936</ArticleId><ArticleId IdType="pubmed">31067237</ArticleId></ArticleIdList></Reference><Reference><Citation>Coylewright M, Keevil JG, Xu K, et al. . Pragmatic study of clinician use of a personalized patient decision aid integrated into the electronic health record: an 8-year experience. Telemed J E Health 2020;26:597&#x2013;602. 10.1089/tmj.2019.0112</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/tmj.2019.0112</ArticleId><ArticleId IdType="pubmed">31381477</ArticleId></ArticleIdList></Reference><Reference><Citation>Healthwise I . Atrial fibrillation: should I take an anticoagulant to prevent stroke?
2015. Available: https://www.healthwise.net/ohridecisionaid/Content/StdDocument.aspx?DOCHWID=tx2209</Citation></Reference><Reference><Citation>Montori VM, Shah ND, Pencille LJ, et al. . Use of a decision aid to improve treatment decisions in osteoporosis: the osteoporosis choice randomized trial. The American Journal of Medicine 2011;124:549&#x2013;56. 10.1016/j.amjmed.2011.01.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2011.01.013</ArticleId><ArticleId IdType="pubmed">21605732</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care 2007;19:349&#x2013;57. 10.1093/intqhc/mzm042</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/intqhc/mzm042</ArticleId><ArticleId IdType="pubmed">17872937</ArticleId></ArticleIdList></Reference><Reference><Citation>Marmor MF, Kellner U, Lai TYY, et al. . Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology 2016;123:1386&#x2013;94. 10.1016/j.ophtha.2016.01.058</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2016.01.058</ArticleId><ArticleId IdType="pubmed">26992838</ArticleId></ArticleIdList></Reference><Reference><Citation>Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol 2014;132:1453&#x2013;60. 10.1001/jamaophthalmol.2014.3459</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaophthalmol.2014.3459</ArticleId><ArticleId IdType="pubmed">25275721</ArticleId></ArticleIdList></Reference><Reference><Citation>Fasano S, Pierro L, Pantano I, et al. . Longterm hydroxychloroquine therapy and low-dose aspirin may have an additive effectiveness in the primary prevention of cardiovascular events in patients with systemic lupus erythematosus. J Rheumatol 2017;44:1032&#x2013;8. 10.3899/jrheum.161351</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.161351</ArticleId><ArticleId IdType="pubmed">28507183</ArticleId></ArticleIdList></Reference><Reference><Citation>Akhavan PS, Su J, Lou W, et al. . The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus. J Rheumatol 2013;40:831&#x2013;41. 10.3899/jrheum.120572</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.120572</ArticleId><ArticleId IdType="pubmed">23588942</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Irastorza G, Egurbide MV, Pijoan JI, et al. . Effect of Antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 2006;15:577&#x2013;83. 10.1177/0961203306071872</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203306071872</ArticleId><ArticleId IdType="pubmed">17080912</ArticleId></ArticleIdList></Reference><Reference><Citation>Izmirly P, Kim M, Costedoat-Chalumeau N. The prospective open label preventive approach to congenital heart block with hydroxychloroquine (patch) study demonstrates a reduction in the recurrence rate of advanced block. Annual American College of Rheumatology 2019.</Citation></Reference><Reference><Citation>L&#xe9;gar&#xe9; F, Kearing S, Clay K, et al. . Are you SURE?: assessing patient decisional conflict with a 4-item screening test. Can Fam Physician 2010;56:e308&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2920798</ArticleId><ArticleId IdType="pubmed">20705870</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Connor A. User manual&#x2014;decisional conflict scale (10 item question format) [document on the Internet]. Ottawa: Ottawa Hospital Research Institute, 1993.</Citation></Reference><Reference><Citation>Almeida-Brasil CC, Hanly JG, Urowitz M, et al. . Flares after hydroxychloroquine reduction or discontinuation: results from the systemic lupus International collaborating clinics (SLICC) inception cohort. Ann Rheum Dis 2022;81:370&#x2013;8. 10.1136/annrheumdis-2021-221295</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221295</ArticleId><ArticleId IdType="pmc">PMC8862090</ArticleId><ArticleId IdType="pubmed">34911705</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>